실적분석 2026년 8월 26일

Phibro Animal Health Group ($PAHC) FY2026 Q4 Earnings Analysis — Revenue and Adjusted EPS Both Beat Expectations

Earnings Scorecard

Revenue: $397 million (year-over-year +5%, expected $378 million) ✅ Beat

EPS: Adjusted $0.85 (expected $0.73) ✅ Beat

Guidance: Newly issued — FY2027 revenue $1.55 billion to $1.60 billion, adjusted EPS $3.41 to $3.59

Stock Reaction: Extended hours +4.63% ($37.76) — as of 08-27 06:01 Korea Standard Time

The Positives

Adjusted EPS beat: Adjusted EPS of $0.85 came in roughly 16% above the $0.73 estimate

Margin expansion: Gross margin of 33.9%, up 4.9 percentage points year-over-year

Record annual revenue: FY2026 revenue of $1.52 billion (+17%), adjusted EBITDA +39%

The company, whose core business is animal health pharmaceuticals and mineral nutrition products, saw profitability step up on higher volumes and an improved product mix. Adjusted EBITDA strength also expanded, and tariff refund gains provided a partial boost to gross profit.

The Negatives

Brazil regulatory uncertainty: Therapeutic indication for virginiamycin not secured; guidance reflects only minimum revenue contribution

Plant shutdown: Chicago Heights facility slated for closure in summer 2027, affecting approximately 100 employees

Slower growth guidance: Based on the midpoint, FY2027 revenue growth comes in at roughly 4%

The forward guidance the company provided is built on the assumption that the Brazilian regulatory issue will not be resolved in the near term. Management indicated that if approval is secured, there is room to slightly exceed the outlook.

What Management Said

Newly appointed CEO Daniel Bendheim explained that the three-year company-wide efficiency program has formally concluded and that its benefits are already reflected in the results. He emphasized that next year's outlook incorporates the Brazilian virginiamycin regulatory uncertainty on a conservative basis.

Market Reaction and Key Points Ahead

With revenue and adjusted EPS both exceeding expectations and the guidance already having baked in regulatory risk, the print appears to have triggered relief buying.

Status and timing of Brazilian approval for the virginiamycin therapeutic indication

Scale of one-time costs tied to the Chicago Heights plant relocation and shutdown

Whether FY2027 revenue and margins hold the midpoint of guidance